Journal Article

Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter study

Kasai, Akihito, Shintake, Hiroaki, Nakayama, Makiko, Tanaka, Koji, Sekiryu, Tetsuju, Maruko, Ruka, Tamashiro, Tamaki, Maruko, Ichiro, Yamamoto, Akiko, Mori, Ryusaburo, Sugano, Yukinori, Wakatsuki, Yu, Itagaki, Kanako, Koizumi, Hideki, Kawai, Moeko, Kataoka, Keiko, Iida, Tomohiro, Onoe, Hajime, Wakugawa, Sorako, Okada, Annabelle A., Izumi, Takahiko, Hasegawa, Taiji, Ogasawara, Masashi, Terao, Nobuhiro

2022

Overview

Purpose To investigate short-term treatment outcomes of intravitreal brolucizumab (IVBr) for treatment-naïve neovascular age-related macular degeneration (AMD) in a Japanese multicenter study. Study design Retrospective case control study Methods The subjects were 58 eyes of 57 patients with neovascular AMD (43 men and 14 women, mean age 74.6 years) of whom 43 eyes of 42 patients completed initial loading of 3 monthly IVBr injections and were followed for more than 3 months. Best-corrected visual acuity (BCVA) changes, anatomical outcomes, and complications were investigated. Results Of the 43 eyes that completed loading doses, the AMD subtype was type 1 and type 2 macular neovascularization (MNV) in 51%, polypoidal choroidal vasculopathy (PCV) in 42%, and type 3 MNV in 7%. At 3 months after initiating treatment, BCVA significantly improved (P = 0.002) and central retinal thickness significantly decreased (P < 0.0001). At 3 months, complete retinal and subretinal fluid resolution was achieved in 91% of all eyes and complete regression of polypoidal lesions was achieved in 82% of PCV eyes. Iritis occurred in 8 eyes of 8 patients (14%), but resolved using topical or subtenon corticosteroid injection without visual loss in all cases. Conclusions IVBr for treatment-naïve neovascular AMD was effective in the short-term, achieving significantly improved BCVA, good retinal fluid resolution, and a high rate of polypoidal lesion regression. However, iritis was noted in 14% of patients which may limit use of this drug.

• Publisher: Springer Japan,Springer Nature B.V
• Subject: Acuity / Age / Age related diseases / Clinical Investigation / Complications / Eye / Eye diseases / Iritis / Lesions / Macular degeneration / Medical imaging / Medicine / Medicine & Public Health / Monoclonal antibodies / Ophthalmology / Patients / Retina / Vascular diseases / Vascularization / Visual acuity